Keyphrases
Type 1 Diabetes Mellitus (T1DM)
100%
Type I Diabetes
78%
Hypoglycemia
41%
Type 2 Diabetes Mellitus (T2DM)
29%
Continuous Glucose Monitoring
28%
Bionic Pancreas
19%
Reduction Approach
19%
Comparative Effectiveness Studies
19%
Glycemia
19%
Glycemic Control
19%
Older Adults
19%
Multicenter Randomized Trial
19%
Hemoglobin A1c (HbA1c)
19%
Hydroxybutyrate
17%
Breath Acetone
14%
Insulin Withdrawal
14%
Liraglutide
13%
Dapagliflozin
13%
Diabetes
12%
Insulin
11%
Wireless
11%
Ketones
11%
17q12 Deletion Syndrome
9%
Maturity-onset Diabetes of the Young type 5
9%
Insulin Receptor Antibody
9%
Cardiovascular Outcomes
9%
Male Hypogonadism
9%
Serous Ovarian Carcinoma
9%
Mixed Connective Tissue Disease
9%
Control Body
9%
Second-line Therapy
9%
High Prevalence
9%
Rheumatic Diseases
9%
Composite Outcome
9%
Late-onset
9%
Old Age
9%
Autoimmune Disease
9%
Capillary
9%
Randomized Crossover Trial
9%
Plasma Glucose
8%
Severe Hypoglycemia
8%
Treatment Group
7%
Glimepiride
7%
Care Groups
6%
Sitagliptin
6%
Weight Gain
6%
Glucose Level
6%
Adjusted Hazard Ratio
5%
Heart Failure Hospitalization
5%
Median Time
5%
Medicine and Dentistry
Insulin Dependent Diabetes Mellitus
60%
Hypoglycemia
41%
Maturity Onset Diabetes of the Young
29%
Diabetes Mellitus
23%
Glycemic Control
19%
Effectiveness Study
19%
Niacin
19%
Breathing
19%
Hydroxybutyric Acid
17%
Liraglutide
14%
Acetone
14%
Diabetes
14%
Dapagliflozin
13%
Hemoglobin A1c
12%
Body Weight
11%
Type 1 Diabetes
11%
Cardiovascular System
9%
Blood Glucose Monitoring
9%
Krukenberg Tumor
9%
Hypogonadism
9%
Autoantibodies
9%
Mixed Connective Tissue Disease
9%
Insulin Receptor
9%
Capillary
9%
Autoimmune Disease
9%
Glimepiride
8%
Randomized Clinical Trials
8%
Cardiovascular Disease
7%
Treatment Group
7%
Sitagliptin
7%
Severe Hypoglycemia
7%
Glycemic
6%
Care Group
6%
Hazard Ratio
5%
Congestive Heart Failure
5%
Insulin Resistance
5%